About Selecxine

Selecxine was found in Dec 2018 with branch office at Seoul, Korea. Selecxine is a clinical stage private biotech company specialized in the field of immunotherapeutics, developing novel antibodies to cure various life-threatening diseases. Based on the understanding of cancer immunology and protein structural information, Selecxine develops antibodies that bind to specific epitope on target protein for modification and amplification of the desired signal from bifunctional molecules such as cytokines.

Clinical Pipeline Advancement

• Selecxine's SLC-3010 completed phase 1 dose finding as a monotherapy in Korea and US with exciting safety and preliminary efficacy readout.
• We are planning for phase 2 study in 2L RCC, BTC, GC in combination with Axitinib (FPI planned Jan 2026) and
• We are planning for phase 2 study in 1L BTC maintenance in combination with Durvalumab (FPI planned Dec 2025).